ProStrakan Group, an international speciality pharmaceutical is Orexo’s exclusive partner for sales and marketing of Abstral/Rapinyl in Europe. Abstral/Rapinyl will be launched in Sweden in the third quarter of 2008, and across Europe from the end of 2008 under the brand name Abstral.
Torbjorn Bjerke, president and CEO of Orexo, said: “The approval is a fantastic achievement for Orexo and our ability to become a profitable pharmaceutical company. I believe that Abstral will play a major role in the treatment of cancer patients suffering from breakthrough pain.”